Alginic Acid
drugOn this page
Also known as Acidum alginicumAlginateE-400INS NO.400INS-400LandalgineLandalgine pMedisorb aSatialgine hSatialgine h 8
Summary
Alginic Acid (CHEMBL2108894) is a phase-3 clinical-stage unknown (ATC A02BX13); indicated across 6 conditions including gastroesophageal reflux disease and peptic ulcer disease.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- ATC class: A02BX13
- Indications: 6 conditions
- Clinical trials: 30
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108894 |
| Name | Alginic Acid |
| Type | Unknown |
| Max phase | 3 |
| ATC | A02BX13 |
Also known as: Acidum alginicum, Alginate, Alginic acid, E-400, INS NO.400, INS-400, Landalgine, Landalgine p, Medisorb a, Satialgine h, Satialgine h 8, ALGINIC ACID
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| gastroesophageal reflux disease | 3 | MONDO:0007186 | EFO:0003948 |
| peptic ulcer disease | 3 | MONDO:0004247 | HP:0004398 |
| vesicoureteral reflux | 3 | MONDO:0006007 | EFO:0007536 |
| cystic fibrosis | 2 | MONDO:0009061 | MONDO:0009061 |
| obesity disorder | 1 | MONDO:0011122 | EFO:0001073 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 30.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 20 |
| PHASE4 | 4 |
| PHASE3 | 2 |
| PHASE2 | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05629143 | PHASE4 | ACTIVE_NOT_RECRUITING | Primary carE PPi dEprescRibing Trial |
| NCT07611162 | PHASE4 | NOT_YET_RECRUITING | Comparative Effectiveness of Alginate, Magaldrate, Sucralfate, Proton Pump Inhibitors, and Diet in Laryngopharyngeal Reflux Disease |
| NCT02806453 | PHASE4 | UNKNOWN | Effect of Magnesium Alginate on Gastroesophageal Reflux in Infants. |
| NCT03635372 | PHASE4 | COMPLETED | A Comparison of Effectiveness of Oral Sucrolfate, Alginate and Hydrotalcide in Dispeptic Pain Treatment |
| NCT01878526 | PHASE3 | COMPLETED | Gastroesophageal Reflux Treatment in Scleroderma |
| NCT03881722 | PHASE3 | COMPLETED | Effect of Magnesium Alginate in Infants With Gastroesophageal Reflux. |
| NCT07310927 | PHASE2/PHASE3 | COMPLETED | Alginate vs Sucralfate for GERD Symptomatic Relief |
| NCT02157922 | PHASE2 | COMPLETED | A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis |
| NCT02453789 | PHASE2 | COMPLETED | A Study of OligoG in Cystic Fibrosis Subjects With Burkholderia Spp. Infection |
| NCT01101633 | PHASE1 | COMPLETED | The Effect of Sodium Alginate on Appetite Sensation |
| NCT05894096 | Not specified | ACTIVE_NOT_RECRUITING | Air Cold Atmospheric Pressure Plasma Treatment for Acceleration of Venous Ulcer Healing |
| NCT06345989 | Not specified | NOT_YET_RECRUITING | Time and Cost-implications of Intraoral Scans Vs Alginate Impressions |
| NCT06623851 | Not specified | RECRUITING | Digital Versus Conventional Impression on Discomfort and Dental Anxiety Among Preschoolers |
| NCT06899672 | Not specified | NOT_YET_RECRUITING | Analyzing the Effect of Disinfection Additives on the Linear Dimensional Stability of Dental Alginate Impressions: A Quasi-Experimental Comparative Study |
| NCT06978569 | Not specified | NOT_YET_RECRUITING | Comparative Efficacy of ADM Hydrogel vs. Alginate Dressings in Chronic Trauma Wounds |
| NCT00593684 | Not specified | COMPLETED | The Safety Evaluation of Silver Alginate (Algidex™) Dressing in Very Low Birth Weight (VLBW) Infants |
| NCT00904124 | Not specified | COMPLETED | The Effect of Different Types of Dietary Fiber on Satiation |
| NCT00964093 | Not specified | COMPLETED | The Effectiveness of Silver Alginate (Algidex) Patch in the Prevention of Central Line Infections in Very Low Birth Weight Infants |
| NCT01231178 | Not specified | COMPLETED | The Effect of an Alginate Based Beverage on Weight Loss |
| NCT03070444 | Not specified | COMPLETED | Vacuum-formed Retainer Versus Bonded Retainer to Prevent Relapse After Orthodontic Treatment |
| NCT03350958 | Not specified | COMPLETED | Bioactive Dietary Fibres and Obesity |
| NCT03477981 | Not specified | COMPLETED | Acceptability of Dietary Fibre-based Foods |
| NCT03757572 | Not specified | TERMINATED | Alginate Dressings Versus Gauge Dressings After Pilonidal Cyst Resection: Examination of the Quality of Life |
| NCT03860337 | Not specified | COMPLETED | The Effect of Alginate on Carbohydrate and Fat Digestion in a Mixed Meal |
| NCT04589273 | Not specified | UNKNOWN | The Effect of Alginate Supplementation on Weight Management |
| NCT05009576 | Not specified | COMPLETED | Comparative Study Using Negative Pressure Dressing With & Without Silver Alginate to Promote Healing in Chronic Wounds. |
| NCT05154461 | Not specified | COMPLETED | Intestinal Ketone Bodies Interfere With the Glycemic Control |
| NCT05194956 | Not specified | COMPLETED | Orthodontic Patient Experience of Intraoral Scans Versus Alginate Impressions |
| NCT05420571 | Not specified | UNKNOWN | Application of Digital Impression Technology in Children’s Dental Trauma |
| NCT06948617 | Not specified | COMPLETED | Children’s Preferences on Digital and Conventional Impression Techniques |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).